Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-08

Study Completion Date

2022-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the most common complaints of admission to the emergency room is gastroenteritis. One of the most common complaints in acute gastroenteritis is abdominal pain. The aim of our study is to investigate whether hyoscine butylbromide used within the indication has an effect on abdominal pain due to acute gastroenteritis. The main purpose of our study is to reduce the pain of the patient at 30th and 60th minutes compared to 0th minute.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis

NCT02508142

Abdominal Cramps

UNKNOWN PHASE4

Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort

NCT02242292

Colic

COMPLETED PHASE2

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

NCT02242305

Abdominal Pain

COMPLETED PHASE3

Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain

NCT01929044

Intestinal Diseases

COMPLETED PHASE3

Spasmolytic in Upper Gastrointestinal Endoscopy

NCT02576340

Gastroscopy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Gastroenteritis Abdominal Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

2 ml of normal saline injection as placebo

Hyoscine N butylbromide

In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.

Group Type ACTIVE_COMPARATOR

Hyoscine N Butylbromide

Intervention Type DRUG

Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyoscine N Butylbromide

Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis

Intervention Type DRUG

Placebo

2 ml of normal saline injection as placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with watery stools starting in the last 2 weeks and 3 times in 24 hours and abdominal pain

Exclusion Criteria

* Peritonitis
* Hemodynamic instability
* Pregnancy
* Inability to give consent
* Medication given in the emergency room before being included in the study
* Taking pain medication within 4 hours
* Diabetes Mellitus and other neuropathic diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No